T he American College of Cardiology/American Heart Association (ACC/AHA) Task Force on Clinical Practice Guidelines have revised the recommendations for diagnosis of chronic hypertension in adults based on compelling evidence that incremental increases in blood pressure (BP) impact the risk of future cardiovascular disease, as well as clinical complications and death. 1 Formerly classified as prehypertension, the new parameters now consider stage 1 hypertension as systolic BP measurement between 130 and 139 mm Hg or diastolic BP measurement between 80 and 89 mm Hg. Though the updated guidelines extensively outlined the effect of graded BP increases in nonpregnant adults, discussions of pregnancy implications are limited.
It is well documented that women entering pregnancy with chronic hypertension under the previous guidelines (now classified as stage 2 hypertension) are at increased risk of pregnancy-related morbidity, particularly preeclampsia, small-for-gestational-age infants, and iatrogenic preterm delivery compared with normotensive women. [2] [3] [4] Women at high risk for preeclampsia, including women with chronic hypertension, preexisting diabetes mellitus, prior preeclampsia, multiple gestations, renal disease, and autoimmune disease, are treated with aspirin prophylaxis in early pregnancy to reduce this risk. 5, 6 Prior studies have shown maternal and neonatal benefit, minimal harm, and potential cost-effectiveness of treatment with low-dose aspirin. [7] [8] [9] [10] Although the evidence supports the use of aspirin for preeclampsia prevention in women at high risk, the benefit is modest, with most studies showing a 10% to 15% risk reduction in these groups. 9, 11 Stage 1 hypertension, previously classified as prehypertension, is not included in recommendations for aspirin prophylaxis. 5, 6 To our knowledge, no studies have yet evaluated maternal and neonatal outcomes in high-risk women entering pregnancy with stage 1 hypertension by the new ACC/AHA guidelines. We sought to compare maternal and neonatal outcomes among high-risk women with newly identified stage 1 hypertension compared with high-risk normotensive women under the revised guidelines and to assess whether women with an additional risk factor for preeclampsia (ie, stage 1 hypertension) had further benefit from aspirin treatment compared with high-risk normotensive women.
Methods

Study Design
This is a secondary analysis of data collected in a double-blinded, randomized, placebo-controlled trial of low-dose aspirin for prevention of preeclampsia in pregnant women at high risk for preeclampsia. Study data are publicly available through the National Institute of Child Health and Human Development Data and Specimen Hub, and the original study design and findings have been reported previously. 12 Anonymized data and materials have been made publicly available at the Institute of Child Health and Human Development Data and Specimen Hub and can be accessed at http://dash.nichd.nih.gov. Briefly, 4 high-risk pregnant populations (women with [1] chronic hypertension, [2] preexisting insulin-dependent diabetes mellitus, [3] multifetal gestations, or [4] history of preeclampsia) were recruited and enrolled between 13 and 26 weeks of gestation. Participants were randomized to receive either low-dose aspirin (60 mg/d) or placebo, and outcome data were collected by study staff and medical record abstraction. The primary outcome of the original study was preeclampsia diagnosis. Studies were performed as part of the Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network at 13 centers, and all studies were approved and monitored by each institution's respective institutional review board. Subjects provided written informed consent before study participation.
Participants and High-Risk Criteria
Briefly, pregnant women at high risk for preeclampsia were recruited between 13 and 26 weeks of gestation. Eligibility criteria for the 4 high-risk groups included diagnosis of chronic hypertension confirmed by BP of ≥140/90 mm Hg or antihypertension medications, diagnosis of insulin-dependent diabetes mellitus, multifetal gestations confirmed by ultrasound, or previous preeclampsia confirmed by medical record or oral history and certain overlaps of high-risk criteria. 12 Eligible women were assigned to a single-blind medication compliance test, and those who passed were randomly assigned to receive either 60 mg aspirin or placebo (lactose) daily from the time of randomization until delivery.
Outcome Variables
For this analysis, we included women in the preexisting diabetes mellitus and prior preeclampsia groups. We excluded women in the chronic hypertension group because they had a confirmed diagnosis of stage 2 hypertension and women with multiple gestations because early pregnancy hemodynamic changes in twin gestations have been shown to differ from singleton gestations. 13, 14 Of the participants with preexisting diabetes mellitus or prior preeclampsia, women with data available for enrollment BP and maternal and neonatal outcomes were included. Fifteen women (1.5%) were excluded because of missing outcome data. Forty-two women (4.1%) were excluded because of enrollment BPs ≥140/90 (stage 2 hypertension). Maternal BP was measured by study staff in a standardized fashion using a mercury sphygmomanometer as described previously. 15 Multiple cuff sizes were available to ensure appropriate cuff size based on arm circumference. Briefly, patients were allowed to rest for at least 10 minutes before measurement and were seated comfortably during the measurement, which was done in a quiet location with trained staff. For this analysis, participants were classified according to BP measurement at enrollment (≤26 weeks of gestation). Women with a systolic BP of 130 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg were classified with stage 1 hypertension under the recent ACC/AHA guidelines 1 and compared with women with BP <130 mm Hg systolic and 80 mm Hg diastolic. We also performed a sensitivity analysis restricting our sample to women who were enrolled before 20 weeks of gestation (n=635).
Our primary outcome was preeclampsia as adjudicated during the original study, which included both mild and severe preeclampsia. Preeclampsia diagnosis was verified in the original study by medical record review by 3 blinded Maternal Fetal Medicine Unit Network study members. Secondary outcomes included small-for-gestationalage infant, placental abruption, indicated or spontaneous preterm delivery, and neonatal intensive care unit admission. In participants without hypertension or proteinuria at enrollment, preeclampsia was defined using guidelines in place at the time as new onset hypertension (≥140 mm Hg systolic or ≥90 mm Hg diastolic on 2 occasions at least 4 hours apart) plus proteinuria (either ≥300 mg per 24 hours or ≥2+ by dipstick on ≥2 occasions). In normotensive participants with proteinuria at enrollment, preeclampsia diagnosis required thrombocytopenia, elevated liver function tests, or hypertension accompanied by either severe headache, epigastric pain, or sudden increase in proteinuria. Severe preeclampsia was defined as severe hypertension (≥160/110 mm Hg) and proteinuria; urinary protein excretion ≥5 g per day with any degree of hypertension; hypertension complicated by pulmonary edema or thrombocytopenia (≤100 000); hemolysis, elevated liver function tests, and a low platelet count (HELLP syndrome); or eclampsia. Small for gestational age was defined as a birth weight below the 10th percentile for singletons. 16 Indicated preterm delivery was defined as delivery before 37 weeks of gestation for maternal or fetal indications. Spontaneous preterm delivery denotes delivery before 37 weeks after spontaneous preterm labor or premature rupture of membranes. Diagnosis of placental abruption was by clinical findings of vaginal bleeding and uterine tenderness. Neonatal intensive care unit admission was collected from the infant medical record.
Statistical Analysis
Statistical analysis was conducted using STATA software, version 14 (StataCorp, College Station, TX). Continuous variables were compared using Student t tests and Wilcoxon-Mann-Whitney U tests as appropriate. Categorical variables were analyzed using χ 2 or Fisher exact where appropriate. Multivariable analysis included log binomial regression to evaluate the independent association between enrollment systolic and diastolic BP (as a discrete variable: hypertensive versus normal) and preeclampsia in women treated with aspirin and placebo. Adjustment covariates were chosen a priori based on previous literature and included maternal age and prepregnancy body mass index. Results were presented as adjusted risk ratios (RRs) with corresponding 95% confidence intervals (CIs), and a P value <0.05 was considered statistically significant. No adjustments were made for multiple comparisons as preeclampsia was our primary end point.
Results
Participants with preexisting insulin-dependent diabetes mellitus and a history of preeclampsia were included, and those with multifetal gestations and preexisting chronic hypertension (now classified as stage 2 hypertension) were excluded. Therefore, of the 2539 women enrolled in the original study, 1020 were included this analysis ( Table 1 ). The majority of the study population (81%; n=827/1020) was normotensive at enrollment, and approximately one fifth (19%; n=193/1020) were newly identified with stage 1 hypertension according to the current ACC/AHA guidelines. Both groups had similar smoking history and infant birth weights, along with similar racial compositions. The women with stage 1 hypertension tended to be slightly older, be heavier, and deliver earlier.
Women randomized to aspirin prophylaxis started treatment at a mean gestational age of 19.4±4.0 weeks.
Within this high-risk population, 15.1% (n=63/416) of women entering pregnancy as normotensive and randomized to placebo developed preeclampsia (Table 2) . Strikingly, of the women entering pregnancy with stage 1 hypertension and receiving placebo, 39.1% (n=36/92) were diagnosed with preeclampsia (P<0.001 compared with normotensive women). This increased incidence is mainly related to mild preeclampsia, with 8.2% of normotensive women developing mild preeclampsia compared with 27.2% of stage 1 hypertensive women (P=0.002). Thus, in this high-risk population, entering pregnancy with stage 1 hypertension was associated with a >2-fold increased risk of preeclampsia (RR, 2.49; 95% CI, 1.74-3.55) compared with normotensive women. Stage 1 hypertension did not impact the rates of placental abruption, indicated or spontaneous preterm birth, infant birth weight, or neonatal intensive care unit admission in our cohort.
Interestingly, the incidence of preeclampsia in these highrisk women was not reduced among normotensive women receiving low-dose aspirin when compared with normotensive women receiving placebo (14.6%; n=60/411 versus 15.1%; n=63/416, respectively; Table 3 ). This was true across both mild and severe preeclampsia. As shown in Table 4 and Figure  1 , aspirin was not effective in reducing preeclampsia in highrisk normotensive women, with an RR of 0.97 (95% CI, 0.70-1.34) for all preeclampsia, an RR of 0.92 (95% CI, 0.58-1.47) for mild disease, and an RR of 1.01 (95% CI, 0.62-1.66) for severe disease. However, low-dose aspirin appeared to affect rates of preeclampsia and benefit women entering pregnancy with stage 1 hypertension. In women with stage 1 hypertension, low-dose aspirin was associated with a 39% reduction of preeclampsia (RR, 0.61; 95% CI, 0.39-0.94) compared with stage 1 hypertensive women receiving placebo, with a 45% reduction in mild disease (RR, 0.55; 95% CI, 0.31-0.97) and a 25% reduction in severe disease (RR, 0.75; 95% CI, 0.32-1.71).
In a sensitivity analysis, we included only women with an enrollment BP measured before 20-week gestational age (Tables S2 and S3 in the online-only Data Supplement) and confirmed our findings. In this analysis, women with stage 1 hypertension have a similar magnitude of increased maternal and neonatal risks, as well as risk reduction with aspirin as our overall cohort.
Discussion
In this study, application of the current ACC/AHA guidelines in a high-risk population demonstrates that in the setting of other risk factors, the presence of stage 1 hypertension is associated with a significantly increased risk of preeclampsia when compared with high-risk women who are normotensive. In our cohort, women with stage 1 hypertension and an additional risk factor (prior preeclampsia or diabetes mellitus) have a preeclampsia incidence of 39.1% compared with 15.1% in normotensive women with prior preeclampsia or diabetes mellitus. In the original high-risk aspirin trial, women with stage 2 chronic hypertension without another risk factor, in comparison, had a preeclampsia incidence of approximately 
25%
. 12 We also found that among women with another risk factor and stage 1 hypertension, the efficacy of aspirin is notably increased compared with normotensive high-risk women. These findings emphasize the importance of stage 1 hypertension as a potentially additive risk factor in women at high risk for preeclampsia and highlight the possible benefit of aspirin prophylaxis in this population.
This study is limited by the fact that it is an unplanned secondary analysis of a randomized trial, which limits our findings. It is further limited by our lack of prepregnancy BP measurements for reclassification of chronic hypertension diagnoses. Although prepregnancy BPs would be ideal for diagnosis, prior studies have shown that women do not consistently seek primary care outside of pregnancy. Preconception care engagement rates range between 18% and 45% in reproductive-age women with chronic diseases in the United States, thus early pregnancy BPs may be all that is available for the obstetrician. 17 Further, patients were recruited into the study up to a gestational age of 26 weeks. We addressed this in a sensitivity analysis in which we included only women with an enrollment BP measured before 20 weeks of gestation and confirmed our findings (Tables S2 and S3 ). The recently published ASPRE trial (Combined Multimarker Screening and Randomized Patient Treatment With Aspirin for Evidence-Based Preeclampsia Prevention) found that treatment of women at high risk for preterm preeclampsia (based on an algorithm utilizing maternal factors and biophysical and biochemical measurements) with 150 mg of aspirin initiated between 11 and 14 weeks of gestation resulted in a decreased incidence of preterm preeclampsia compared with placebo. 8 Similarly, other studies have shown a substantially reduced risk of preeclampsia in women who initiated treatment before 16 weeks. There were a small number of women in our study who were initiated on low-dose aspirin before 16 weeks (n=258), limiting our ability to compare our findings to this larger study. Further, the dose of aspirin used in the original trial (60 mg) is lower than the dose currently utilized in clinical practice, which ranges from 81 to 160 mg. Our ability to compare our results to the ASPRE trial is limited by our cohort size, with only a small number of women (n=23) developing early preeclampsia (<34 weeks).
The scientific rigor of the standardized measurement of BP by trained study staff is a strength of our study along with the large sample size considering the challenges and burden of conducting a clinical trial in thousands of pregnant participants. However, it is important to note the small number of women within this trial with BPs that met the new ACC/AHA criteria for stage 1 hypertension (n=193). Additionally, this secondary analysis is performed on a cohort recruited between 1989 and 1992. Incontrovertibly, the demographics of this group differ from a contemporaneous cohort with advancing maternal age and increasing rates of obesity. 18 However, given that aspirin is now considered the standard of care in a highrisk population, it is unlikely that a placebo-controlled randomized trial to address this question in a contemporaneous cohort would be ethical. Further study on a low-risk population to address the implications of stage 1 hypertension and the effect of aspirin is warranted.
Although our findings may not seem particularly innovative in a cohort of women who already meet criteria for aspirin prophylaxis, we contend that there are important implications for both an understanding of the pathophysiology of the disease and intervention, as well as identification of target at-risk women for future studies. First, although randomized studies of >30 000 high-risk women have clearly established the benefit of aspirin, the mechanism of action has not yet been identified. 19, 20 A deeper understanding of which high-risk pregnant women are most likely to benefit from aspirin is an important step forward for our field and our comprehension of the pathophysiology of preeclampsia. 21 Our findings support the hypothesis that there are likely many pathways to disease in preeclampsia and that aspirin likely acts along one of those pathways. Further, we contend that these pathways almost certainly differ among the subgroups of women who are considered high risk for preeclampsia. We found that women who are normotensive but at high risk for preeclampsia might only have minimal benefit from aspirin. In our cohort, treatment with aspirin in highrisk women entering pregnancy as normotensive reduced the risk of preeclampsia by 3%, compared with a 39% reduction in women entering pregnancy with stage 1 hypertension. Aspirin resistance is a controversial but documented entity in the cardiology literature that has not been well studied in the obstetric population. [22] [23] [24] Although this may not be especially relevant with administration of a drug that has an extensively studied maternal and fetal safety profile, these findings will become more germane as we begin studying newer interventions for preeclampsia prevention. For example, both statins and metformin are in early stages of randomized trials for preeclampsia risk reduction, both of which have a less favorable risk profile than aspirin. [25] [26] [27] [28] [29] The obvious extension of this is that based on our findings, future trials might consider targeting high-risk women who are normotensive entering pregnancy because those women seem to have possibly only minimal benefit from aspirin prophylaxis.
Perspectives
As the adoption of the ACC/AHA guidelines becomes more widespread, there will be an increasing number of reproductive-age women who will fall into the category of stage 1 hypertension. 1 Thus, this study provides initial evidence on pregnancy outcomes and an approach to management of these women. Our findings suggest that women entering pregnancy with stage 1 chronic hypertension diagnosed by the current ACC/AHA guidelines and an additional risk factor have an increased rate of maternal complications compared with highrisk normotensive women. Our findings also suggest that lowdose aspirin may be particularly an effective prophylaxis to reduce the risk of preeclampsia in this population. Further study using contemporaneous cohorts is needed in this highrisk population. Figure.
Prevalence of preeclampsia in normotensive and stage 1 hypertensive women receiving aspirin or placebo during pregnancy.
